New Ultra-Rapid Insulin Enters First Human Testing to Better Work With Automated Pumps

Current rapid-acting insulins have important limitations when used in automated insulin delivery systems—the pumps and algorithms that help manage blood sugar with minimal user input. Invictus Therapeutics has developed an experimental insulin analog that aims to address this problem by working faster and more predictably within these systems.

The experimental insulin has two notable features: it acts more quickly and closely mimics how the body naturally releases insulin, and it remains stable at room temperature rather than requiring refrigeration. These qualities could help automated systems deliver insulin more effectively and help people achieve better blood sugar control with less daily burden.

Breakthrough T1D, a leading type 1 diabetes research organization, has awarded Invictus Therapeutics funding through an Industry Discovery and Development Partnership (IDDP) to support the first human trial of this insulin. The partnership is part of Breakthrough T1D's broader effort to advance automated insulin delivery systems that reduce the amount of daily management people with type 1 diabetes need to perform.

The Phase 1 trial—the earliest stage of human testing—will be conducted at Profil, a research organization in Germany that specializes in early-phase studies of metabolic and diabetes treatments. Profil is recognized internationally for its expertise in studying how insulin behaves in the body.

If successful, this research could make automated insulin delivery systems work better and require even less attention from users. However, it is important to note that this is early-stage research—the insulin is only now entering human testing for the first time. Several years of additional research will be needed to determine whether it is safe and effective, and whether it will eventually become available to people with type 1 diabetes.

The focus on improving how insulin works within automated systems reflects a broader goal in diabetes research: to create tools that help people manage their condition with less daily decision-making and fewer interruptions to their lives.

Origin: prnewswire.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.